← ANALYST RATINGS · TIPRANKS
Bio-Techne (TECH): analyst forecast and price target
Analyst consensus
Hold0 Buy2 Hold0 Sell
Ratings of 2 analysts in the last 3 months · top analysts only12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $73.00, the highest $73.00, the lowest $73.00. The average is +0.6% from the last price of $72.57.
Analyst ratings 15
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $81.00 | Buy | +11.6% | Reiterated | 23.09.26on TipRanks 19:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $81.00 | Buy | +11.6% | Reiterated | 23.09.26on TipRanks 19:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $79.00 → $81.00+2.5% | Buy | +11.6% | Upgrade | 23.09.26on TipRanks 19:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $77.00 → $78.00+1.3% | Hold | +7.5% | Reiterated | 23.09.26on TipRanks 19:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $83.00 | Buy | +14.4% | Reiterated | 23.09.26on TipRanks 19:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $82.00 → $83.00+1.2% | Buy | +14.4% | Reiterated | 23.09.26on TipRanks 19:05 | — | |
| Dan Leonard★★★★★★★★★★#656 · hits 62% · avg +14.1% | RBC Capital | $73.00 | Hold | +0.6% | Reiterated | 12.08.26on TipRanks Aug 13 07:15 | −0.1%next day −0.8% · 5 days +0.8% | ↗ |
| Matt Larew★★★★★★★★★★#816 · hits 63% · avg +19.3% | William Blair | — | Hold | — | Reiterated | 12.08.26on TipRanks 13:25 | −0.1%next day −0.8% · 5 days +0.8% | ↗ |
| Kyle Boucher★★★★★★★★★★#3152 · hits 100% · avg +25.0% | TD Cowen | $65.00 → $73.00+12.3% | Hold | +0.6% | Downgrade | 30.06.26on TipRanks Jul 1 05:51 | −1.1%next day +0.6% · 5 days +0.6% | ↗ |
| Robert Wasserman★★★★★★★★★★#2200 · hits 44% · avg +9.2% | Benchmark Co. | — | Hold | — | Downgrade | 30.06.26on TipRanks 07:17 | −1.1%next day +0.6% · 5 days +0.6% | ↗ |
| Patrick B Donnelly★★★★★★★★★★#2106 · hits 54% · avg +6.0% | Citi | $70.00 → $73.00+4.3% | Hold | +0.6% | Downgrade | 29.06.26on TipRanks Jun 26 17:05 | −1.8%next day −1.1% · 5 days −1.3% | ↗ |
| Brandon Couillard★★★★★★★★★★#287 · hits 63% · avg +18.4% | Wells Fargo | $62.00 | Buy | −14.6% | Reiterated | 26.06.26on TipRanks Jun 29 05:25 | +1.1%next day −1.8% · 5 days −3.2% | ↗ |
| Steven Etoch★★★★★★★★★★#2413 · hits 86% · avg +59.3% | Stephens | $68.00 → $73.00+7.4% | Hold | +0.6% | Downgrade | 26.06.26on TipRanks 08:35 | +1.1%next day −1.8% · 5 days −3.2% | ↗ |
| Catherine Ramsey Schulte★★★★★★★★★★#864 · hits 53% · avg +11.2% | Robert W. Baird | $49.00 → $73.00+49.0% | Hold | +0.6% | Reiterated | 26.06.26on TipRanks 06:50 | +1.1%next day −1.8% · 5 days −3.2% | ↗ |
| Justin Bowers★★★★★★★★★★#8679 · hits 47% · avg 0.0% | Deutsche Bank | $66.00 → $73.00+10.6% | Hold | +0.6% | Downgrade | 26.06.26on TipRanks 04:40 | +1.1%next day −1.8% · 5 days −3.2% | ↗ |
| Puneet Souda★★★★★★★★★★#2942 · hits 45% · avg +4.1% | Leerink Partners | $73.00 | Hold | +0.6% | Downgrade | 25.06.26on TipRanks 11:30 | +19.9%next day +1.1% · 5 days −1.2% | ↗ |
| David Westenberg★★★★★★★★★★#602 · hits 56% · avg +17.3% | Piper Sandler | $65.00 | Hold | −10.4% | Initiated | 11.06.26on TipRanks 06:00 | +1.2%next day −0.6% · 5 days +5.8% | ↗ |
| Daniel Markowitz CFA★★★★★★★★★★#1752 · hits 61% · avg +22.3% | Evercore ISI | $54.00 → $50.00−7.4% | Hold | −31.1% | Assigned | 07.05.26on TipRanks 08:15 | +7.7%next day −5.8% · 5 days −14.4% | ↗ |
| Daniel Arias★★★★★★★★★★#1848 · hits 50% · avg +8.0% | Stifel Nicolaus | $65.00 → $50.00−23.1% | Hold | −31.1% | Reiterated | 07.05.26on TipRanks 07:40 | +7.7%next day −5.8% · 5 days −14.4% | ↗ |
| Paul Knight★★★★★★★★★★#4215 · hits 45% · avg +3.5% | KeyBanc | — | Hold | — | Reiterated | 07.05.26on TipRanks 05:31 | +7.7%next day −5.8% · 5 days −14.4% | ↗ |
| David Toung★★★★★★★★★★#1098 · hits 63% · avg +9.1% | Argus Research | $65.00 → $68.00+4.6% | Buy | −6.3% | Assigned | 20.11.25on TipRanks 09:50 | +3.1%next day +3.8% · 5 days +5.1% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Bio-Techne
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $73.00 at a price of $72.47 (+0.7%); now: $73.00 at $72.57 (+0.6%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Buy | 6 | 9 | 9 | 3 | 0 | 0 |
| Hold | 5 | 14 | 14 | 12 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 03.11.26 (Q1 2027, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.44 (from $0.42 to $0.49). Last quarter: $0.52.
Sales
Next quarter’s sales estimate — $293M (from $287M to $298M). Last quarter: $321M.
Best top-analyst consensus in the sector · Healthcare
About Bio-Techne
- CEO: Kim Kelderman
- Employees: 3,000
- 614 McKinley Place N.E., Minneapolis, MN, 55413, US
- www.bio-techne.com
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Data from the stock’s TipRanks forecast page, read 87 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗